---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023109"
form_type: "8-K"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:25:31.227146+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xtant Medical Q2 2025 revenue $35.4M (+18% YoY), net income $3.6M, raises FY guidance

## Summary
- Revenue $35.4M up 18% YoY; gross margin improved to 68.6% from 62.1%.
- Net income $3.6M ($0.02 diluted EPS) vs net loss $3.9M in Q2 2024.
- Adjusted EBITDA $6.9M vs loss of $0.6M; operating cash flow $1.2M vs use of $5.1M.
- FY2025 revenue guidance raised to $131-$135M (prior $127-$131M), growth 11%-15%.
- Announced sale of non-core Coflex/CoFix/OUS assets to Companion Spine for ~$19.2M.

## SEC filing metadata
- accession: 0001641172-25-023109
- form_type: 8-K
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000164117225023109/0001641172-25-023109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000164117225023109/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023109
- JSON: https://secwatch.observer/filing/0001641172-25-023109.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023109.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.